CoChat

Augmentation With Citalopram for Suicidal Ideation in Middle-Aged and Older Outpatients With Schizophrenia and Schizoaffective Disorder Who Have Subthreshold Depressive Symptoms: A Randomized Controlled Trial

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Article AbstractObjective: To examine the effects of citalopram augmentation of antipsychotics on suicidal ideation in middle-aged and older people with schizophrenia and subthreshold depressive symptoms.Method: In this placebo-controlled trial conducted from September 1, 2001, to August 31, 2007, 198 outpatients ≥†‰40 years old with DSM-IV-diagnosed schizophrenia or schizoaffective disorder and subthreshold depressive symptoms were randomly assigned to flexible-dose citalopram (n†‰=†‰104) or placebo (n†‰=†‰94) augmentation of their antipsychotic for 12 weeks. Depression was measured with the Hamilton Depression Rating Scale (HDRS) and Calgary Depression Rating Scale (CDRS). Primary suicidal ideation measures were the Clinical Global Impressions-Severity of Suicide scale (CGI-SS) and the InterSePT Scale for Suicidal Thinking (ISST); secondary outcomes were the Scale for Suicidal Ideation (SSI), Beck Hopelessness Scale (BHS), HDRS item 3, and CDRS item 8.Results: Compared to placebo, at the final visit, citalopram was associated with lower BHS scores (4.21 vs 4.98; P†‰<†‰.05) and lower likelihood of having suicidal ideation on the ISST (17.7% vs 38.7%; P†‰<†‰.005) and HDRS item 3 (14.4% vs 22.6%; P†‰<†‰.05). Among the 114 participants with no baseline suicidal ideation, there were no significant differences between citalopram and placebo regarding "emergent" ideation on either primary outcome. Among the 55 participants with baseline suicidal ideation, fewer treated with citalopram had endpoint ideation on the ISST (28.6% vs 66.7%; P†‰<†‰.05). Significantly more depression responders than nonresponders went from having baseline suicidal ideation to no suicidal ideation on both the ISST (75.0% vs 31.4%; P†‰<†‰.05) and CGI-SS (84.6% vs 31.3%; P†‰<†‰.05).Conclusions: Treatment-emergent suicidal ideation was no more common with citalopram than placebo. In participants with baseline suicidal ideation, citalopram reduced suicidal ideation, especially in those whose depressive symptoms responded to treatment.Trial Registration: clinicaltrials.gov Identifier: NCT00047450J Clin Psychiatry 2010;71(7):915-922Submitted: September 10, 2009; accepted November 3, 2009.Online ahead of print: March 9, 2010 (doi:10.4088/JCP.09m05699gre).Corresponding author: Sidney Zisook, MD, University of California San Diego, Department of Psychiatry, 3350 La Jolla Village Drive, San Diego, CA 92161 (szisook@ucsd.edu).

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.09m05699gre

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Cited by

See all 45

Metadata

Authors
Zisook, S., Kasckow, J. W., Lanouette, N. M., Golshan, S., Fellows, I., Vahia, I., Mohamed, S., & Rao, S.
Affiliations
University of California San Diego (US)
Corresponding author
Zisook, Sidney
Venue
The Journal of Clinical Psychiatry
Published
2010-03-09
Volume
71
Issue
07
Pages
915-922
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2088136344
Cited by
45
References
45
Citations by year
2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 6 · 2019: 2 · 2018: 1 · 2016: 2 · 2015: 3 · 2014: 3 · 2013: 3 · 2012: 5
FWCI
3.71
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (P30MH080002, MH 66248, R01 MH6398, MH-19934, R01MH063931, P30MH066248, T32MH019934)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
Keywords
citalopram, antidepressant augmentation, suicidal ideation, schizophrenia, schizoaffective disorder, subthreshold depression, middle-aged and older adults, antipsychotic augmentation, hopelessness, suicide risk reduction, outpatients, Hamilton Depression Rating Scale
MeSH terms
Suicide Prevention, Adult, Aged, Depression, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Personality Inventory, Psychotic Disorders, Schizophrenia, Schizophrenic Psychology, Suicide, Antipsychotic Agents, Citalopram, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Augmentation With Citalopram for Suicidal Ideation in Middle-Aged and Older Outpatients With Schizophrenia and Schizoaffective Disorder Who Have Subthreshold Depressive Symptoms: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.4088/jcp.09m05699gre
The paper
Zisook, S., Kasckow, J. W., Lanouette, N. M., Golshan, S., Fellows, I., Vahia, I., Mohamed, S., & Rao, S. (2010). Augmentation With Citalopram for Suicidal Ideation in Middle-Aged and Older Outpatients With Schizophrenia and Schizoaffective Disorder Who Have Subthreshold Depressive Symptoms: A Randomized Controlled Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.09m05699gre

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.